Empagliflozin treatment is also associated with a lower risk of HF, all-cause mortality, and end-stage renal disease in comparison with dipeptidyl peptidase-4 (DPP-4) inhibitors in routine clinical practice in Japan, South Korea, and Taiwan.40 This evidence concerns the gene DPP4 and chronic kidney disease.